PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31202641-9	2019	Placebo-adjusted reductions from baseline with bempedoic acid also were significant for total cholesterol (-10%; P = .014), non-high-density lipoprotein cholesterol (-13%; P = .015), apolipoprotein B (-15%; P = .004), and high-sensitivity C-reactive protein (-44%; P = .002).	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	47-61	apolipoprotein B	Homo sapiens	183-199	
33783450-4	2021	Furthermore, bempedoic acid has also been associated with the improvement of other biomarkers, including reduced apolipoprotein B and high-sensitivity C-reactive protein, effects that can increase the clinical benefits of this treatment.	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	13-27	apolipoprotein B	Homo sapiens	113-129	
34172394-9	2021	Compared with placebo, bempedoic acid significantly lowered apolipoprotein B, non-high-density lipoprotein cholesterol, and total cholesterol (nominal P < .001 for all), and high-sensitivity C-reactive protein (P = .029).	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	23-37	apolipoprotein B	Homo sapiens	60-76	
32609313-15	2020	Decreases in non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein levels were greater with bempedoic acid vs placebo.	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	157-171	apolipoprotein B	Homo sapiens	74-90	
33025951-4	2020	Bempedoic acid given at a dosage of 180 mg orally once daily produces a highly significant reduction in low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B and importantly also in high-sensitivity C-reactive protein.	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	0-14	apolipoprotein B	Homo sapiens	210-226	
32689862-9	2020	Conclusions BA is associated with a significant reduction in low-density lipoprotein cholesterol, total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B, and hs-CRP compared with standard treatment.	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	12-14	apolipoprotein B	Homo sapiens	159-175	
30922146-7	2019	Significant reductions with bempedoic acid versus placebo were also observed in non-high-density lipoprotein cholesterol (-17.9%), total cholesterol (-14.8%), apolipoprotein B (-15.0%), and high-sensitivity C-reactive protein (-24.3%; P&lt;0.001 for all comparisons).	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	28-42	apolipoprotein B	Homo sapiens	159-175	
33818688-6	2021	In clinical trials conducted in patients with or at risk for atherosclerotic cardiovascular disease or familial heterozygous hypercholesterolemia, bempedoic acid in combination with statins and/or ezetimibe significantly reduced LDL-C, apolipoprotein B, and high-sensitivity C-reactive protein compared with placebo.	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	147-161	apolipoprotein B	Homo sapiens	236-252	
33328138-3	2021	METHODS: We performed a meta-analysis including randomized trials of bempedoic acid therapy, reporting low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B and hsCRP with a minimum of 4 weeks of follow-up.	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	69-83	apolipoprotein B	Homo sapiens	202-218	
33328138-9	2021	CONCLUSION: Our data suggests that the use of bempedoic acid significantly reduces the levels of all atherogenic lipid markers, including LDL-C, non-HDL-C and apolipoprotein B.	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	46-60	apolipoprotein B	Homo sapiens	159-175	
33276805-13	2020	In addition, bempedoic acid also resulted in a significant reduction in TC, non-HDL-C, ApoB and hsCRP level.	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid	13-27	apolipoprotein B	Homo sapiens	87-91